Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 5/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.38 |
| ▸ | MLKL | Q8NB16 | 1/20 | 0.38 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 5/20 | 0.34 |
| ▸ | TRPV4 | Q9HBA0 | 4/20 | 0.34 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.32 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.31 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.31 |
| ▸ | CSF1R | P07333 | 3/20 | 0.31 |
| ▸ | ANO1 | Q5XXA6 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4979936 | 0.92 | EPHB4 (0.33) | KDRRIPK1MLKLRIPK3TRPA1 | |
| SCHEMBL4976614 | 0.86 | KDR (0.35) | KDRRIPK1MLKLRIPK3TRPA1 | |
| SCHEMBL4975127 | 0.84 | EPHB4 (0.37) | KDREPHB4 | |
| SCHEMBL4978787 | 0.83 | LMNA (0.38) | KDRANO1 | |
| SCHEMBL4978714 | 0.83 | EPHB4 (0.38) | KDREPHB4 | |
| SCHEMBL4978627 | 0.83 | KDR (0.38) | KDRRIPK1MLKLRIPK3 | |
| SCHEMBL4976580 | 0.81 | MEN1 (0.38) | KDREPHB4ANO1 | |
| SCHEMBL4980547 | 0.81 | KDR (0.34) | KDRTRPA1 | |
| SCHEMBL4980171 | 0.81 | EPHB4 (0.33) | KDREPHB4 | |
| SCHEMBL4977994 | 0.80 | EPHB4 (0.34) | KDRRIPK1MLKLRIPK3EPHB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7338959-B2 | Diamino-pyrimidines and their use as angiogenesis inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-03-04 | — | — | US | claimed |
| US-20050234083-A1 | Diamino-pyrimidines and their use as angiogenesis inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-10-20 | — | — | US | claimed |
| US-7338959-B2 | Diamino-pyrimidines and their use as angiogenesis inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-03-04 | — | — | US | disclosed |
| EP-1487824-B1 | DIAMINO-PYRIMIDINES AND THEIR USE AS ANGIOGENESIS INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2007-06-20 | — | — | EP | disclosed |
| US-20050234083-A1 | Diamino-pyrimidines and their use as angiogenesis inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-10-20 | — | — | US | disclosed |
| EP-1487824-A1 | DIAMINO-PYRIMIDINES AND THEIR USE AS ANGIOGENESIS INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003074515-A1 | DIAMINO-PYRIMIDINES AND THEIR USE AS ANGIOGENESIS INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234083-A1 | Diamino-pyrimidines and their use as angiogenesis inhibitors | TIE1, TEK, KDR | KDR 3/4885RIPK1 2052/4885MLKL 1502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.